Analysis: Part D is main cause of $500B Medicare slowdown

Prescription drug spending (or Part D) has accounted for more than 60 percent of the slowdown in Medicare benefits since 2011, according to an analysis presented in Health Affairs.

Unfortunately, “the outsized role that Part D has played in the Medicare slowdown is bad budget news because it may prove fleeting,” according to authors Loren Adler, research director for the Committee for a Responsible Federal Budget (CRFB) and Adam Rosenberg, policy analyst at CRFB.

Read more below:

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”